伊沃西单抗(一种程序性细胞死亡蛋白-1与血管内皮生长因子双特异性抗体)作为晚期或转移性免疫治疗初治非小细胞肺癌一线或二线治疗的1b期研究
这项1b期研究(HARMONi-5)评估了伊沃西单抗单药用于晚期免疫治疗初治非小细胞肺癌一线或二线治疗的安全性和疗效。108例患者接受不同剂量方案,总体客观缓解率为39.8%,疾病控制率为86.1%。≥3级治疗相关不良事件发生率为22.2%,导致死亡的治疗相关不良事件发生在3例(2.8%)鳞状非小细胞肺癌患者中。
要点
- 总体客观缓解率为39.8%,疾病控制率为86.1%。
- PD-L1 TPS≥1%和≥50%患者的客观缓解率分别为51.4%和57.1%。
- ≥3级治疗相关不良事件发生率为22.2%,导致死亡的治疗相关不良事件发生在3例(2.8%)鳞状非小细胞肺癌患者中。
核心结论
- 伊沃西单抗单药治疗在晚期或转移性非小细胞肺癌患者中耐受性良好,并显示出有前景的疗效。
研究设计与样本
- 这是一项1b期研究(HARMONi-5),纳入108例晚期或转移性免疫治疗初治非小细胞肺癌患者,接受伊沃西单抗静脉给药:10 mg/kg每3周一次、20 mg/kg每2周一次、20 mg/kg每3周一次或30 mg/kg每3周一次。
- 主要终点为安全性和依据实体瘤疗效评价标准1.1版评估的客观缓解率。
主要发现
- 数据截止至2022年10月5日,中位随访时间为10.4个月(范围:8.4-10.9个月)。
- 全部患者的客观缓解率为39.8%,疾病控制率为86.1%。
- PD-L1 TPS<1%、≥1%和≥50%患者的客观缓解率分别为14.7%、51.4%和57.1%。
- 在67例接受一线伊沃西单抗治疗的PD-L1阳性患者中,10 mg/kg每3周一次、20 mg/kg每2周一次、20 mg/kg每3周一次和30 mg/kg每3周一次剂量组的客观缓解率分别为33.3%、52.6%、60.0%和75.0%。
- ≥3级治疗相关不良事件发生于24例患者(22.2%),导致治疗中断的治疗相关不良事件发生于1例患者(0.9%),导致死亡的治疗相关不良事件发生于3例(2.8%)鳞状非小细胞肺癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study (HARMONi-5) aimed to evaluate the safety and efficacy of ivonescimab (a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor) as first- or second-line monotherapy in patients with advanced immunotherapy-naive NSCLC. METHODS: Eligible patients received intravenous ivonescimab 10 mg/kg every 3 weeks (Q3W), 20 mg/kg every 2 weeks (Q2W), 20 mg/kg Q3W, or 30 mg/kg Q3W. The primary end points were safety and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: At data cutoff (October 5, 2022), 108 patients were enrolled and received ivonescimab. Programmed death ligand-1 tumor proportion score (TPS) was greater than or equal to 1% in 74 patients (68.5%), including 35 (32.4%) with TPS greater than or equal to 50%. The median follow-up was 10.4 months (range: 8.4-10.9 mo). For all patients, ORR and disease control rate were 39.8% and 86.1%, respectively. ORR by TPS was 14.7%, 51.4%, and 57.1% in patients with TPS less than 1%, greater than or equal to 1%, and greater than or equal to 50%, respectively. In the 67 programmed death ligand-1-positive patients receiving first-line ivonescimab, the ORR was 33.3%, 52.6%, 60.0%, and 75.0% at the doses of 10 mg/kg Q3W, 20 mg/kg Q2W, 20 mg/kg Q3W, and 30 mg/kg Q3W, respectively. Grade greater than or equal to 3 treatment-related adverse events (TRAEs) were observed in 24 patients (22.2%). TRAEs leading to treatment discontinuation occurred in one patient (0.9%). TRAEs leading to death occurred in three patients (2.8%) with squamous NSCLC. The occurrence of grade greater than or equal to 3 TRAEs and grade greater than or equal to 3 bleeding events in squamous versus nonsquamous NSCLC patients was 25.5% versus 18.9% and 0.0% versus 1.9%, respectively. CONCLUSIONS: Ivonescimab monotherapy was well tolerated and found to have a promising efficacy in patients with advanced or metastatic NSCLC. CLINICALTRIALS: gov identifier: NCT04900363.
引用
- Wang L, Luo Y, Ren S, et al. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. J Thorac Oncol. 2023. PMID: 37879536. doi:10.1016/j.jtho.2023.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。